A decrease in the systemic immune-inflammation index during 6 months of cardiac resynchronization therapy independently predicted a favorable clinical and echocardiographic response in patients with heart failure (OR 0.982).
Cohort (n=78)
Does the systemic immune-inflammation index (SII) predict response to cardiac resynchronization therapy in patients with heart failure?
A decrease in the systemic immune-inflammation index (SII) during the first 6 months of cardiac resynchronization therapy is a significant independent predictor of favorable clinical and echocardiographic response in patients with heart failure.
Effect estimate: OR 0.982 (95% CI 0.970-0.995)
p-value: p=0.006
Aim: To investigate the utility of systemic immune-inflammation index (SII) in predicting response to cardiac resynchronization therapy (CRT) among patients with heart failure (HF). Method: A total of 78 patients with HF who underwent CRT device implantation were included in this 6month follow up study. Data on laboratory findings including complete blood count, blood biochemistry and SII as well as the transthoracic echocardiography findings were recorded at baseline prior to CRT device implantation and 6 months after CRT.
Uğuz et al. (Thu,) conducted a cohort in Heart failure (n=78). Cardiac resynchronization therapy was evaluated on Response to CRT (≥15% decrease in LVESV, ≥10% increase in EF, and ≥1 class NYHA improvement) (OR 0.982, 95% CI 0.970-0.995, p=0.006). A decrease in the systemic immune-inflammation index during 6 months of cardiac resynchronization therapy independently predicted a favorable clinical and echocardiographic response in patients with heart failure (OR 0.982).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: